Patent intelligence · Companies
Company patent strength
Non-educational filers ranked by their patent portfolio. Grant rate and lapsed share expose where high filing volume is not matched by granted patents. Domestic filers lead — toggle to foreign applicants to see who is entering the Indian market.
Free to browse the ranking. Sign into open a filer's full profile — inventors, filing trend and quality index. See how we rank.
Why this page exists — and how to read it
Filing volume and IP quality are different things. This leaderboard ranks non-educational filers by portfolio, but the grant-rate and lapsed sorts are where the judgement lives: they separate companies whose filings survive examination from those accumulating paper.
- Investors
- High grant rate on steady filing usually means a real R&D engine; big volume with a high lapsed share is a red flag worth asking about.
- Founders & operators
- These are the incumbents and potential acquirers in your space — open a filer to see the walls you'd build against.
- Corporate & R&D
- Benchmark competitors' portfolios and grant rates; toggle to foreign to watch who is entering the Indian market.
💬 The grant-rate sort applies a 20-filing floor so tiny portfolios can't top the list.
3,207 foreign filers with 5+ patents · page 27
| # | Filer | Patents↓ | Granted↓ | Lapsed↓ | Pending↓ | Active |
|---|---|---|---|---|---|---|
| 1301 | ELANCO TIERGESUNDHEIT | 11 | 19.1% | 2 | 8 | 2022–2025 |
| 1302 | ENERTECH INTERNATIONAL | 11 | 00% | 6 | 5 | 2022–2024 |
| 1303 | EVOTEC INTERNATIONAL | 11 | 19.1% | 1 | 9 | 2021–2025 |
| 1304 | FIBERHOME TELECOMMUNICATION TECHNOLOGIES | 11 | 545.5% | 0 | 6 | 2022–2024 |
| 1305 | FREEZIO | 11 | 19.1% | 2 | 8 | 2022–2023 |
| 1306 | GAPLAST | 11 | 218.2% | 0 | 9 | 2021–2025 |
| 1307 | GEORG FISCHER ROHRLEITUNGSSYSTEME | 11 | 00% | 0 | 11 | 2022–2025 |
| 1308 | GEORGIAMUNE | 11 | 00% | 0 | 11 | 2022–2026 |
| 1309 | GEVO | 11 | 00% | 0 | 11 | 2022–2026 |
| 1310 | GREAT WALL MOTOR | 11 | 11100% | 0 | 0 | 2022–2022 |
| 1311 | GROUP14 TECHNOLOGIES | 11 | 00% | 0 | 11 | 2023–2025 |
| 1312 | GRST INTERNATIONAL | 11 | 00% | 9 | 2 | 2023–2024 |
| 1313 | GUANGZHOU SHIYUAN ELECTRONICS | 11 | 654.5% | 0 | 5 | 2021–2025 |
| 1314 | HSP HOCHSPANNUNGSGER TE | 11 | 00% | 0 | 11 | 2024–2025 |
| 1315 | HUBEI RT ADVANCED MATERIALS GROUP | 11 | 00% | 0 | 11 | 2023–2024 |
| 1316 | HUECK FOLIEN GESELLSCHAFT M B H | 11 | 654.5% | 0 | 5 | 2020–2026 |
| 1317 | ICEOTOPE GROUP | 11 | 327.3% | 1 | 7 | 2021–2025 |
| 1318 | IP2IPO INNOVATIONS | 11 | 00% | 0 | 11 | 2023–2025 |
| 1319 | JAPAN AVIATION ELECTRONICS INDUSTRY | 11 | 00% | 0 | 11 | 2023–2026 |
| 1320 | JAPAN SCIENCE AND TECHNOLOGY AGENCY | 11 | 218.2% | 0 | 9 | 2022–2026 |
| 1321 | JCB RESEARCH | 11 | 00% | 0 | 11 | 2022–2026 |
| 1322 | JEPLAN | 11 | 19.1% | 2 | 8 | 2022–2025 |
| 1323 | JOHN COCKERILL | 11 | 19.1% | 1 | 9 | 2021–2025 |
| 1324 | JOHNSON CONTROLS TYCO IP HOLDINGS | 11 | 545.5% | 0 | 6 | 2018–2024 |
| 1325 | JOHNSON MATTHEY CATALYSTS GERMANY | 11 | 19.1% | 4 | 6 | 2022–2024 |
| 1326 | JSW AKTINA SYSTEM | 11 | 00% | 0 | 11 | 2024–2026 |
| 1327 | KAESER KOMPRESSOREN SE | 11 | 00% | 0 | 11 | 2023–2025 |
| 1328 | KINDEVA DRUG DELIVERY L P | 11 | 00% | 10 | 1 | 2022–2024 |
| 1329 | KIRTI | 11 | 00% | 0 | 11 | 2023–2025 |
| 1330 | KOCKS TECHNIK KG | 11 | 00% | 0 | 11 | 2024–2024 |
| 1331 | KOEI CHEMICAL | 11 | 00% | 3 | 8 | 2022–2025 |
| 1332 | KOSKA FAMILY | 11 | 00% | 0 | 11 | 2022–2026 |
| 1333 | L3VEL | 11 | 19.1% | 0 | 10 | 2022–2025 |
| 1334 | LARGAN MEDICAL | 11 | 436.4% | 0 | 7 | 2022–2024 |
| 1335 | LIVEARENA TECHNOLOGIES | 11 | 00% | 0 | 11 | 2024–2025 |
| 1336 | MAGNA SEATING | 11 | 00% | 0 | 11 | 2024–2026 |
| 1337 | MAGOTTEAUX INTERNATIONAL | 11 | 00% | 2 | 9 | 2022–2025 |
| 1338 | MEDICALAI | 11 | 00% | 0 | 11 | 2023–2024 |
| 1339 | MEDSHINE DISCOVERY | 11 | 00% | 2 | 9 | 2022–2025 |
| 1340 | MITSUI CHEMICALS CROP LIFE SOLUTIONS | 11 | 00% | 0 | 11 | 2023–2026 |
| 1341 | NEWRACOM | 11 | 00% | 0 | 11 | 2023–2026 |
| 1342 | NIPPON PISTON RING | 11 | 218.2% | 0 | 9 | 2022–2025 |
| 1343 | NOVELIS KOBLENZ | 11 | 872.7% | 0 | 3 | 2022–2025 |
| 1344 | NUMAB THERAPEUTICS | 11 | 19.1% | 1 | 9 | 2020–2025 |
| 1345 | PACIFIC INDUSTRIAL DEVELOPMENT | 11 | 00% | 9 | 2 | 2022–2025 |
| 1346 | PERKINS ENGINES | 11 | 19.1% | 0 | 10 | 2022–2026 |
| 1347 | PHARMAZELL | 11 | 19.1% | 2 | 8 | 2022–2024 |
| 1348 | PHONONIC | 11 | 00% | 0 | 11 | 2022–2025 |
| 1349 | PRINCIPIA BIOPHARMA | 11 | 00% | 3 | 8 | 2022–2026 |
| 1350 | PROMEGA | 11 | 00% | 0 | 11 | 2022–2026 |
Educational institutes are excluded — see the institute leaderboard. Attribution is by patent assignee record; a jointly-owned patent is credited to each co-owner, so a co-filed patent counts for every company on it. "Lapsed" = abandoned, withdrawn, deemed-withdrawn or refused; "Pending" = awaiting examination or in prosecution. Want to filter by technology or value category? Browse the filer explorer →
Rankings use patent-registry status (grant rate, examination, claim depth) as a quality proxy — directional, not advice; see methodology. Read the ranking methodology →